FIELD: biotechnology.
SUBSTANCE: antibodies or their antigen-binding fragments, which bind to PD-1, and their use for the production of a bispecific antibody are presented. Nucleic acid, expression vectors, a pair of expression vectors, cells for expression of an anti-PD-1 antibody or its antigen-binding fragment, a method for the production of an anti-PD-1 antibody or its antigen-binding fragment, an antibody-drug conjugate for increasing an immune response, a method for the treatment of an individual having malignant neoplasm, a method for reduction in a tumor growth rate, a method for destruction of a tumor cell, and pharmaceutical compositions for increasing an immune response are also disclosed.
EFFECT: invention allows for obtainment of new antibodies or their antigen-binding fragments, which have high affinity to PD-1.
68 cl, 6 tbl, 20 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
